Reaffirmed: Sangamo Biosciences (NASDAQ:SGMO) Hold Rating Maintained by Wedbush; $6.0 Target in Place

February 23, 2018 - By Peter Erickson

 Reaffirmed: Sangamo Biosciences (NASDAQ:SGMO) Hold Rating Maintained by Wedbush; $6.0 Target in Place

Investors sentiment decreased to 1.57 in Q3 2017. Its down 0.02, from 1.59 in 2017Q2. It dropped, as 17 investors sold Sangamo Therapeutics, Inc. shares while 32 reduced holdings. 27 funds opened positions while 50 raised stakes. 51.93 million shares or 2.16% more from 50.83 million shares in 2017Q2 were reported.

Voya Investment Mgmt Ltd Liability Com owns 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 38,027 shares. Metropolitan Life Ins Commerce Ny has invested 0.01% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Janney Montgomery Scott Lc stated it has 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Commonwealth Equity Service reported 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). State Of Wisconsin Investment Board holds 53,000 shares or 0% of its portfolio. First Mercantile Co invested in 0.01% or 4,611 shares. Massachusetts-based Frontier Management Com Lc has invested 0.05% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). 580,000 were accumulated by Opaleye. Macquarie has 1,800 shares. Gru One Trading L P stated it has 219,157 shares or 0.03% of all its holdings. Baker Bros Advisors L P reported 2.11 million shares or 0.26% of all its holdings. Cubist Systematic Strategies Ltd Limited Liability Company reported 0.02% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Citigroup invested in 59,436 shares. Cookson Peirce & has invested 0.07% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Beacon Cap, a Ohio-based fund reported 4,950 shares.

Since September 1, 2017, it had 0 insider purchases, and 8 sales for $1.88 million activity. 5,000 Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares with value of $85,545 were sold by Conner Edward R.. $445,597 worth of stock was sold by RINGO WILLIAM R on Wednesday, September 20. $237,159 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares were sold by Mento Steven J.

Sangamo Biosciences (NASDAQ:SGMO) Rating Reaffirmed

Wedbush now has a $6.0 PT on the $2.11B market cap company or -75.95 % downside potential. In analysts report revealed to investors on Wednesday, 15 November, Sangamo Biosciences (NASDAQ:SGMO) shares have had their Hold Rating reiterated by research analysts at Wedbush.

Investors sentiment decreased to 1.57 in Q3 2017. Its down 0.02, from 1.59 in 2017Q2. It dropped, as 17 investors sold Sangamo Therapeutics, Inc. shares while 32 reduced holdings. 27 funds opened positions while 50 raised stakes. 51.93 million shares or 2.16% more from 50.83 million shares in 2017Q2 were reported.

Voya Investment Mgmt Ltd Liability Com owns 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 38,027 shares. Metropolitan Life Ins Commerce Ny has invested 0.01% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Janney Montgomery Scott Lc stated it has 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Commonwealth Equity Service reported 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). State Of Wisconsin Investment Board holds 53,000 shares or 0% of its portfolio. First Mercantile Co invested in 0.01% or 4,611 shares. Massachusetts-based Frontier Management Com Lc has invested 0.05% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). 580,000 were accumulated by Opaleye. Macquarie has 1,800 shares. Gru One Trading L P stated it has 219,157 shares or 0.03% of all its holdings. Baker Bros Advisors L P reported 2.11 million shares or 0.26% of all its holdings. Cubist Systematic Strategies Ltd Limited Liability Company reported 0.02% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Citigroup invested in 59,436 shares. Cookson Peirce & has invested 0.07% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Beacon Cap, a Ohio-based fund reported 4,950 shares.

Since September 1, 2017, it had 0 insider purchases, and 8 sales for $1.88 million activity. 5,000 Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares with value of $85,545 were sold by Conner Edward R.. $445,597 worth of stock was sold by RINGO WILLIAM R on Wednesday, September 20. $237,159 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares were sold by Mento Steven J.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Ratings Coverage

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 70% are positive. Sangamo Biosciences has $25.0 highest and $4 lowest target. $18.20’s average target is -27.05% below currents $24.95 stock price. Sangamo Biosciences had 23 analyst reports since August 8, 2015 according to SRatingsIntel. The rating was downgraded by Piper Jaffray on Wednesday, October 19 to “Neutral”. The firm earned “Hold” rating on Thursday, August 10 by Piper Jaffray. The rating was maintained by Wedbush with “Buy” on Wednesday, September 2. The firm earned “Overweight” rating on Wednesday, November 15 by PiperJaffray. The firm earned “Hold” rating on Wednesday, November 15 by Wedbush. Wells Fargo initiated the stock with “Outperform” rating in Friday, December 4 report. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has “Buy” rating given on Thursday, September 3 by JP Morgan. JP Morgan maintained the stock with “Overweight” rating in Saturday, August 8 report. Jefferies maintained the shares of SGMO in report on Wednesday, September 2 with “Buy” rating. On Monday, August 14 the stock rating was maintained by Wedbush with “Hold”.

The stock decreased 1.77% or $0.45 during the last trading session, reaching $24.95. About 3.70M shares traded or 108.65% up from the average. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 29.78% since February 23, 2017 and is uptrending. It has outperformed by 13.08% the S&P500.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on February, 27. They expect $-0.18 EPS, down 28.57 % or $0.04 from last year’s $-0.14 per share. After $-0.15 actual EPS reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 20.00 % negative EPS growth.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $2.11 billion. The companyÂ’s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

More notable recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: Zacks.com which released: “Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 14.4% in Session February …” on February 23, 2018, also Prnewswire.com with their article: “Case Western Reserve and Sangamo Therapeutics Announce $11 Million NIH Grant …” published on February 07, 2018, Marketwatch.com published: “Gilead’s Kite and Sangamo Therapeutics to collaborate on engineered cell …” on February 22, 2018. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were released by: Prnewswire.com and their article: “Sangamo Therapeutics Announces Fourth Quarter and Full Year 2017 Conference …” published on February 20, 2018 as well as Prnewswire.com‘s news article titled: “Sangamo Therapeutics Presents Initial Safety Data from CHAMPIONS Genome …” with publication date: February 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: